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Objective: Endovascular repair (EVR) of abdominal aortic aneurysm (AAA) is being performed with increasing frequency
worldwide. No studies have a complete follow-up of more than 4 years. Our study objective was to assess the long-term
results and the durability of a first-generation stent graft with complete 7-year follow-up.
Methods: Between March 1994 and May 1995, 23 consecutive patients underwent treatment with the Chuter stent graft
at a single center. All patients underwent computed tomographic scan before discharge, at 3 and 6 months, and annually
thereafter. The data were prospectively collected on all patients. The median follow-up period was 72.5 months (range,
0.2 to 91 months). None of the patients were lost to follow-up.
Results: Among these 21 men and two women with a median age of 69 years (range, 52 to 85 years), 11 (47.8%) were at
high risk. The 30-day technical success rate was 87%. Acute (30-day) complications were one graft deployment failure
(4.3%) that necessitated an immediate conversion, 20 intraoperative graft limb kinks (87%), all of which needed
additional Wallstent (Schneider, Minneapolis, Minn) placement, four renal failures (17.4%), one type Ia endoleak
complicated with AAA rupture (4.3%), and three perioperative deaths (13%). Late complications were eight type I or II
endoleaks (34.8%) after a mean delay of 23.9 months (range, 3 to 69 months), 13 proximal stent migrations (56.5%) after
a mean delay of 29.6 months (range, 7 to 58 months), six graft limb thromboses (26.1%) after a mean delay of 38.7
months (range, 3 to 71 months), one AAA rupture (4.3%), and 11 deaths (47.8%), with five AAA-related deaths (21.7%).
The 3-year, 5-year, and 7-year cumulative endoleak rates were 34%, 41%, and 49%, respectively; the cumulative migration
rates were 66%, 75%, and 75%, respectively; and the cumulative open surgery rates were 30%, 50%, and 50%, respectively.
At the same intervals, the cumulative survival rates for any death were 69%, 56%, and 49%, respectively; the cumulative
survival rates for AAA-related deaths were 82%, 82%, and 73%, respectively; and the cumulative secondary success rates
were 54%, 28%, and 28%, respectively.
Conclusion: This studies emphasizes the need for close lifelong surveillance of AAAs treated with EVR. Despite the small
population of this series, a long-term follow-up highlights that the first-generation homemade stent graft evaluated in
this study failed to adequately protect the patient from AAA-related death and that most of the serious complications
were related to a late failure of the aortic neck attachment. Better proximal fixation of the aortic stent graft is essential to
improve the durability of EVR. (J Vasc Surg 2003;37:367-73.)
The technical feasibility of endovascular repair (EVR)
of infrarenal abdominal aortic aneurysm (AAA) has now
been established over the past 12 years. Because the pri-
mary objective of treatment is to prevent the patient from
any AAA-related death, the crucial issue with respect to
EVR is its effectiveness in the long term. Many excellent
reports have a comparatively short period of follow-up and
provide quite good short-term results.1-6 Several authors
recently reported their mid-term results and reached differ-
ing conclusions, with either encouraging findings7-10 or
increasing occurrence of late failure.11-14 None of these
reports have a complete follow-up of more than 4 years.
The aim of this study was to provide a long-term perspec-
tive on the durability of a first-generation aortic stent graft
with complete 7-year follow-up.
METHODS
Between March 1994 and May 1995, 23 consecutive
patients underwent primary EVR of infrarenal AAAs with
the Chuter stent graft. This study was approved by the local
ethics committee. Written informed consent was obtained
from each patient. The data were prospectively collected on
all patients until November 2001. None were lost to fol-
low-up. The median follow-up period was 72.5 months
(range, 0.2 to 91 months).
Patients were considered at high risk for intervention if
they had American Society of Anesthesiologists grade III or
IV disease or ruptured AAA. All patients underwent thin-
cut (5-mm or less) abdominal and pelvic spiral computed
tomographic (CT) scan with contrast enhancement and
preoperative angiography before EVR. The eligibility crite-
ria were: AAA of more than 5 cm in diameter or symptom-
atic and inflammatory or ruptured AAA without serious
systemic infection. Patients were excluded on anatomic
grounds if: 1, the proximal neck diameter was more than 26
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mm and the length was less than 15 mm; 2, the proximal
neck diameter change from proximal to distal was more
than 5 mm (conical neck); 3, the proximal neck angulation
was more than 75 degrees; 4, the common iliac artery
implantation site diameter was more than 15 mm and the
length was less than 20 mm; 5, the external iliac artery
diameter was less than 6 mm; and 6, the intestinal perfusion
depended on prograde flow through the inferior mesen-
teric artery (IMA), such as the presence of a large IMA,
extensive collateralization between the IMA and the supe-
rior mesenteric artery (SMA), flow from the IMA to the
SMA, or stenosis of the celiac and SMA. In most cases, the
stent graft was oversized 2 to 4 mm larger than the aortic
implantation site and 1 to 2 mm larger than the iliac
implantation sites. None of the patients had preoperative
IMA or lumbar artery embolization to prevent postopera-
tive endoleaks.
The Chuter stent graft existed in straight aortoaortic,
tapered aortouniiliac, and bifurcated aortobiiliac configu-
rations. It consisted of a tubular, tapered, or unibody
bifurcated conventional graft material (Cooley Verisoft,
Meadox Medicals, Inc, Oakland, NJ) and two (for straight
grafts) or three (for bifurcated grafts) Gianturco Z stents
(Cook, Critical Care, Inc, Ellettsville, Ind) that attached
the ends of the graft to the arterial wall. The proximal stent
carried four caudally directed barbs and four hooks (Fig 1).
All the graft limbs measured 8 mm in diameter with small
bell bottoms to prevent leakage. The distal stents were
unbarbed. The stent graft was custom made for each pa-
tient, on the basis of the findings of preoperative imaging.
The concept of the bifurcated device was to deliver the
entire bifurcated stent graft and manipulate the contralat-
eral limb into position with catheters, wires, and pull su-
tures.
All procedures were performed with general anesthesia
in the operating room by a team consisting of a vascular
surgeon, a radiologist, and two assistants, with a mobile
C-arm (Siemens, Siremobil 2000, Erlangen, Germany).
Bilateral common femoral arteriotomies were used, except
for tubular stent grafts that required unilateral arteriotomy.
The technique of Chuter stent graft placement has been
previously described.4,5,15 Postimplantation angiography
was performed to assess graft positioning, patency, kinking,
and endoleaks. Wallstents (Schneider, Minneapolis, Minn)
were routinely placed within the unsupported limbs of the
graft where completion angiography showed kinking or
stenosis. Endoleaks were treated during the operation with
additional endovascular or open measures.
All patients underwent clinical examination and CT
scan before discharge, at 3 months and 6 months, and
annually thereafter. All the CT scans were analyzed by a
radiologist. Perioperative mortality was defined as death
within 30 days of operation. The endoleaks were classified
according to the White-May16,17 and Harris18 definitions:
type Ia endoleak from proximal fixation site, type Ib from
distal fixation site, type IIa from IMA, type IIb from lumbar
artery, type III from defects in the stent graft, and type IV
from transient porosity of the graft. Migration was consid-
ered significant when the proximal stent had slipped distally
5 mm or more. The occurrence of renal failure was defined
as an increase in plasma creatinine level of more than 20%
from preoperative value during the same hospital admis-
sion. During the follow-up period, a variation in maximal
AAA diameter was considered significant at 5 mm or more
between two CT scans more than 3 months apart. The
technical success, clinical success, continuing success, and
secondary success were expressed as defined by the Ad Hoc
Committee for Standardized Reporting Practices in Vascu-
lar Surgery of The Society for Vascular Surgery/Interna-
tional Society for Cardiovascular Surgery.19 Data were
expressed as mean standard deviation. The Kaplan-Meier
method was used to examine the cumulative migration and
endoleak rates and the cumulative freedom from open
surgery and secondary success rates. Life-table survival anal-
ysis was determined for all causes of death and for AAA-
related deaths. The AAA-related deaths included perioper-
ative deaths, deaths related to secondary procedures, open
conversions, and AAA ruptures.
RESULTS
This single center experience of EVR with Chuter stent
graft was carried out on 21 men and two women with a
median age of 69 years (range, 52 to 85 years). Eleven
procedures (47.8%) were conducted in patients at high risk;
two of these patients (8.7%) had emergency ruptures. The
AAA preoperative sizing is reported in Table I. Fourteen
Fig 1. Chuter stent graft with proximal Gianturco Z stent.
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bifurcated (60.9%), eight aortouniiliac (34.8%), and one
aortoaortic (4.3%) stent grafts were used.
Twenty-two patients (95.6%) had complications re-
lated to the EVR during this median follow-up period of
72.5 months (Table II). One graft deployment failure
(4.3%) necessitated an immediate conversion (first case).
Intraoperative graft limb kinks occurred in 20 patients
(87%), all of which were treated with additional Wallstent
placement. No intraoperative death occurred. Three pa-
tients (13%) died within 30 days of the operation, two of
whom were at high risk: one multisystem organ failure at
day 17 in the patient with immediate conversion, one
rupture at day 6 related to a primary type Ia endoleak and
despite a conversion for periaortic ligature placement, and
one renal failure at day 14 after successful EVR of a rup-
tured AAA. Four patients (17.4%) had perioperative renal
failure. Three of the patients died within 30 days of opera-
tion, and one had spontaneously regression. The 30-day
technical success rate was 87%.
Secondary endoleaks were observed in eight patients
(34.8%) with a mean delay of 23.9 months (range, 3 to 69
months). One case of type Ib endoleak (4.3%) occurred
with the single aortoaortic device. No type III or type IV
endoleaks were observed. Thirteen patients (56.5%) had
proximal stent migrations that occurred after a mean delay
of 29.6 months (range, 7 to 58 months). Stent graft
migrations led to secondary type Ia endoleaks in four
patients and to graft limb occlusions in three patients. Table
III describes the impact of endoleak and migration on
variation in maximal AAA diameter (the three perioperative
deaths have been excluded). Kaplan-Meier cumulative en-
doleak, migration, and open surgery curves are shown in
Fig 2. The 3-year, 5-year, and 7-year cumulative endoleak
rates were 34%, 41%, and 49%, respectively; the cumulative
Table I. Characteristics of patients who underwent EVR
Characteristics
Elective AAA 21 (91.3%)
Ruptured AAA 2 (8.7%)
Patients at high risk 11 (47.8%)
ASA grade
I 4 (17.4%)
II 10 (43.5%)
III 7 (30.4%)
IV 2 (8.7%)
Risk factors
CABG 4 (17.4%)
IHD 9 (39.1%)
Hypertension 9 (39.1%)
POAD 1 (4.3%)
COAD 1 (4.3%)
Renal failure 2 (8.7%)
AAA preoperative sizing* (mm)
AAA diameter 61.9  11.2
Aortic neck length 31.4  12
Aortic neck diameter 22.4  1.8
RA-Bif length 127.8  18.2
RCI length 56.5  10
LCI length 53  9.5
RCI diameter 13.9  2.7
LCI diameter 12.7  2.8
Device
Bifurcation 14 (60.9%)
Aortouniiliac 8 (34.8%)
Aortoaortic 1 (4.3%)
*Mean value  standard deviation.
CABG, Coronary artery bypass graft; IHD, ischemic heart disease; POAD,
peripheral occlusive arterial disease; COAD, chronic obstructive airways
disease; RA-Bif, renal arteries–aortic bifurcation; RCI, right common iliac;
LCI, left common iliac.
Table II. Complications detected during long-term
follow-up
Complications
Acute (30-day) complications and operative
outcome
Graft deployment failure 1 (4.3%)
Immediate conversion 1 (4.3%)
Intraoperative Wallstent placement 20 (87%)
Occluded internal iliac artery 0
Occluded renal artery 0
Endoleak (type Ia) 1 (4.3%)
Renal failure 4 (17.4%)
AAA rupture 1 (4.3%)
Secondary procedure 1 (4.3%)
Perioperative (30-day) mortality 3 (13%)
Duration* (min) 195.4  88.3
Blood loss* (mL) 914.5  1373.4
ICU stay* (d) 1.1  1.8
Hospital stay* (d) 11.1  4.4
Late complications
Endoleak 8 (34.8%)
Type Ia/b 5 (21.7%)/1 (4.3%)
Type IIa/b 1 (4.3%)/2 (8.7%)
Migration 13 (56.5%)
Delay* (mo) 29.6  12.1
Length* (mm) 36.3  21.4
Thrombosis 6 (26.1%)
Delay* (mo) 38.7  23.2
Ischemic complication 2 (8.7%)
Septic complication 0
Renal failure 0
AAA rupture 1 (4.3%)
Secondary procedure 11 (47.8%)
Overall mortality 11 (47.8%)
Related death 5 (21.7%)
Unrelated death 6 (26.1%)
Endoleak type Ia, proximal fixation site; Ib, distal fixation site; IIa, IMA; IIb,
lumbar artery.
*Mean value  standard deviation.
ICU, Intensive care unit.
Table III. Variation of maximal AAA diameter after
EVR according to presence of endoleak or migration
Enlarging
AAA
Stable
AAA
Shrinking
AAA
Endoleak, migration 4 (20%) 0 1 (5%)
Endoleak, no migration 3 (15%) 0 0
Migration, no endoleak 0 3 (15%) 5 (25%)
No migration, no endoleak 1 (5%) 1 (5%) 2 (10%)
8 (40%) 4 (20%) 8 (40%)
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migration rates were 66%, 75%, and 75%, respectively; and
the cumulative open surgery rates were 30%, 50%, and 50%,
respectively. Six patients (26.1%) had graft limb thrombo-
ses that occurred after a mean delay of 38.7 months (range,
3 to 71 months). Only two of these patients (8.7%) were
symptomatic with lower limb ischemia: one was nonpro-
gressive and the other needed a femorofemoral bypass. The
3-year, 5-year, and 7-year cumulative clinical success rates
were 47%, 24%, and 24%, respectively, and the cumulative
continuing success rates were 28%, 6%, and 6%, respec-
tively.
Secondary procedures were undertaken in 12 patients
(52.2%) with a mean delay of 29.5 months (range 0.2-66
months) as shown in Table IV. Open repair was performed
in nine patients (39.1%) with type Ia endoleaks, migrations,
or graft limb thromboses. These included open suture of
the stent graft top end (n 5), stent graft explantation and
open aneurysm repair (n 2), periaortic ligature placement
(n  1), and femorofemoral bypass (n  1). Two of these
patients died in the postoperative period, and the remain-
ing seven patients had effective repairs. EVR was under-
taken in three patients (13%) with type Ib or type II
endoleaks. These included embolization (n  2) and addi-
tional stent graft placement (n  1). During the follow-up
period, all of these patients had an enlarging AAA related to
persistant endoleak, but no rupture occurred. Conservative
management was adopted in seven patients (30.4%). Five of
these patients had a shrinking AAA, and one had a stable
AAA, whereas one patient with an enlarging AAA related to
type IIb endoleak and migration died from late rupture.
The overall mortality concerned 11 patients (47.8%).
Six patients (26.1%) died of causes unrelated to the AAA
(three were at high risk): cancers (n 3 patients at 37, 45,
and 54 months), liver failure (n 1 patient at 25 months),
myocardial infarction (n  1 patient at 29 months), and
acute cholangitis (n  1 patient at 42 months). Five pa-
tients (21.7%) died of AAA-related causes (three at high
risk): perioperative deaths (n  3 patients), hemorrhagic
complications after secondary open repair (n 1 patient at
17 months), and late AAA rupture (n  1 patient at 74
months). Kaplan-Meier cumulative survival and secondary
success curves are shown in Fig 3. The 3-year, 5-year, and
7-year cumulative survival rates were 69%, 56%, and 49%,
respectively, for any death and were 82%, 82%, and 73%,
respectively, for AAA-related death. At the same intervals,
the cumulative secondary success rates were 54%, 28%, and
28%, respectively.
DISCUSSION
The advent of endovascular techniques has permitted
the management of aortic aneuryms with a less aggressive
approach, avoiding laparotomy and aortic cross clamping.
During this period, significant advances have been made.
At the beginning, in most of the series, stent grafts were
reserved for patients who were considered at high risk for
standard open repair. When the perioperative safety of the
Fig 2. Life-table analysis of freedom from endoleak, migration, and open surgery.
Table IV. Management of Chuter stent graft failures
n Endoleak Migration Thrombosis
Open repair 9 4 7 3
Delay* (mo) 25.5  19 35.4  14.4 26  23.3
Endovascular repair 3 3 0 0
Delay* (mo) 34.3  22.5 – –
Conservative
management
7 2 6 3
*Mean value  standard deviation.
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procedures improved and good short-term outcome was
shown, stent grafts were used to treat others.3 In advocat-
ing EVR for these patients, a critical analysis of late out-
come is necessary.
Even though a relatively large number of endovascular
procedures have been analyzed, most patients in these
study populations had a follow-up period of less than 2
years. Some earlier studies of mid-term results after EVR of
AAA have been reported with mixed conclusions. Ohki et
al11 performed 239 EVRs for nonruptured AAAs, 86% in
patients at high risk. During follow-up to 75 months (but
mean, 15.7 months), complications occurred with increas-
ing frequency and the overall life-table patient survival rate
at 5 years was 37%. May et al9 compared two generations of
stent grafts and showed that survival and probability of
graft failure were significantly higher with first-generation
stent grafts than with second-generation stent grafts during
a follow-up period of 48 months. Sultan et al8 reported 36
EVRs with a mean follow-up period of 29 months. Their
technical, clinical, continuous, and secondary success rates
were 78%, 91%, 89%, and 91%, respectively. Zarins et al7
reviewed 1192 patients treated with the AneuRx stent graft
and reported a rupture-free rate of 99.5% at 3 years and an
overall survival rate of 86% at 3 years.
None of the patients in this series were lost to follow-up
(median duration, 72.5 months). The overall mortality rate
was 48%, and the 7-year cumulative survival rate was 49%
for any death and 73% for AAA-related deaths. The inci-
dence rate of complications was higher than that of most
other series. First-generation devices and the learning curve
probably contributed to a relatively high complication rate.
Above all, the duration of follow-up has permitted detec-
tion of late complications, which are not encountered
during the first 2 or 3 years. Prinssen et al13 explained that
failure of the proximal attachment system related to aortic
enlargement may not become apparent before 3 or 4 years
of follow-up have elapsed. Ho¨lzenbein et al20 reported that
26% of their 173 patients needed a secondary procedure
during mid-term follow-up because complications ap-
peared even after periods of more than 2 years.
Migration represents one of the main problems en-
countered with the Chuter stent graft. This occurred at a
mean delay of 30 months, despite the presence of hooks
and barbs on the proximal stent. However, several explants
showed the hooks and barbs were trapped in the cloth and
not in the aorta as a result of “muzzle” loading.5,21,22 Two
stent graft explantations were reported in this series. In
these two cases, the structural integrity of the conventional
graft material was respected and the examination of the
Gianturco Z stents showed no stent, hooks, or barb frac-
ture. As shown on the Kaplan-Meier life-table analysis, the
7-year cumulative migration rate was 75%. Stent graft mi-
grations have already been described with the Chuter and
the Ivancev-Malmo¨ devices23 as a consequence of limited
oversizing, ineffective barbs, and high distal force related to
the change in diameter between aortic and iliac segments,
which greatly increased the incident energy and force of
flowing blood. Harris et al24 showed that migration is an
important cause of proximal fixation site endoleak and is
significantly associated with rupture. Factors contributing
to migration of stent grafts have been emphasized by the
Malmo¨ group22: inadequate fixation mechanism and im-
proper device placement in the perirenal aorta and adverse
proximal neck morphology (wide, 30 mm; short, 10
Fig 3. Life-table analysis of survival and secondary success.
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mm; conical, calcified and thrombus-lined necks). Several
strategies have been used to avoid migration, including
more hooks, higher radial force, and suprarenal attachment
of the proximal stent. These lessons are reflected in more
recent device designs, such as the Zenith stent graft.2,6
Moreover, it has been shown that in some cases there is a
continuous aortic enlargement of approximately 1 mm/y
at the level of the proximal endovascular anastomosis.13
With the current practice of oversizing the stent graft to the
proximal neck,25 a loss of the endovascular seal may not
become manifest until 3 or 4 years after EVR of AAA is
performed. If the potential for migration continues for the
life of the patient, the lack of durability is a concern,
especially for patients at good risk. An effective way to
prevent subsequent migration of stent graft would be to
attach the prosthetic graft to the aortic neck with a system
of endovascular staples or sutures. As recently proposed by
Trout and Tanner,26 we are developing a prototype of
nitinol endovascular staple to provide a more secure prox-
imal anastomosis of the stent graft.
The 39.1% incidence rate of endoleak that was found in
this series is inside the reported range, which varies from
10% to 44%.1-3,12,19,27-29 Most of the type Ia endoleaks
were caused by migration. One patient died at day 6 after
surgery of rupture related to a primary type Ia endoleak.
This emphasizes that type I endoleak is an important risk
factor for postoperative rupture and justifies immediate
intervention (open or endovascular). Another patient died
at 74 months after surgery of late rupture related to a type
IIb endoleak and migration. Type II endoleaks may also
result in aneurysm rupture.30 Persistent sac pressure or
endotension causes it to expand and rupture.31 The Euro-
star experience24 has shown that, even if direct measure-
ment of endotension is not yet possible, continued expan-
sion or reexpansion of the sac after surgery is a strong
indication of its presence and, therefore, a strong indication
for secondary intervention. In this series, the increase in
AAA diameter seemed to be more directly related to en-
doleak than to migration. Nearly all cases of endoleak with
or without migration were associated with an increasing
size in maximal AAA diameter, whereas all cases of migra-
tion without endoleak had stable or shrinking AAA proba-
bly because there were small migrations not yet resulting in
leaks.
The late graft limb thromboses that occurred in this
series are probably related to the use of an unsupported
stent graft. Intraoperative Wallstent placement was used
where kinking or stenosis was seen on completion angiog-
raphy. This was a frequent (87%) finding. Fully supported
stent grafts have been found to provide improved patency
compared with unsupported stent grafts.32 Unibody un-
supported devices have advantages in avoiding the separa-
tion of modular graft limb components that may occur as
the AAA morphology changes and lead to type III en-
doleak. Two complications notable by their absence are
embolism and colon ischemia. The policy of systemic hep-
arinization and preserving internal iliac artery flow, if at all
possible, is partly attributable to concern for colonic perfu-
sion because EVR affords no opportunity for IMA reim-
plantation.
The need for secondary procedures is an important
indicator of long-term success of EVR. Many of the recent
publications involve a relative limited follow-up. In the
Eurostar registry, a population of patients that had at least
1 year of follow-up was studied. Overall, 18% of these had
a secondary procedure, occurring after a mean delay of 14
months, and the rate of freedom from intervention at 4
years was 62%.14 In our series, 54.5% of patients had a
secondary procedure and the 3-year, 5-year, and 7-year
cumulative open surgery rates were 30%, 50%, and 50%,
respectively, reflecting the high rate of late complications.
Most of the secondary procedures occurred from the third
year of follow-up and were open repairs. At the beginning
of our experience, we had no appropriate device to treat
with an endovascular method a proximal migration of
unsupported stent graft; we preferred to realize an aortic
cross clamping and a direct suture between the aorta and
the top of the stent graft. The high incidence rate of late
secondary procedure emphasizes the need for lifelong sur-
veillance. In most of the series,33-36 the 5-year cumulative
survival rate in patients who underwent operation for AAA
(except ruptured AAA) ranged from 63% to 83%; a popu-
lation with same age and gender had a 5-year survival rate of
80% to 85%. As expected in a population with nearly 50%
patients at high risk, the 5-year cumulative survival rate was
56% for any death and 82% for AAA-related deaths.
CONCLUSION
EVR of AAA has been proven to be technically feasible.
Stent grafts can fail in a greater number of ways and with
greater frequency than standard AAA grafts placed during
an open operation.12,36 It is necessary to keep patients
informed that maintenance procedures may be necessary.
The stent graft was deployed successfully in most cases with
effective aneurysm exclusion. The late complications in-
cluded type Ia endoleak, stent graft migration, and graft
limb thrombosis. Although the latter problem has been
surmounted by fully supported limbs, the other two remain
a challenge to the durability of EVR, even if migration
should not occur with such a high incidence with the
new-generation stent grafts. All patients managed with a
first-generation aortic stent graft and with stable or enlarg-
ing AAA related to endoleak or migration should have an
open or EVR to avoid any AAA rupture. Despite the small
population of this series, a long-term follow-up underlines
that the first-generation homemade stent graft evaluated in
this study failed to adequately protect the patient from
AAA-related death and that most of the serious complica-
tions were related to a late failure of the aortic neck attach-
ment. This state of affairs may change as better devices with
improved proximal fixation or new systems of endovascular
suture become available to prevent leaks and slips.
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